AR095542A1 - Compuestos heterocíclicos y sus usos - Google Patents
Compuestos heterocíclicos y sus usosInfo
- Publication number
- AR095542A1 AR095542A1 ARP140101155A ARP140101155A AR095542A1 AR 095542 A1 AR095542 A1 AR 095542A1 AR P140101155 A ARP140101155 A AR P140101155A AR P140101155 A ARP140101155 A AR P140101155A AR 095542 A1 AR095542 A1 AR 095542A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclic compounds
- preparation
- methods
- pharmaceutical formulations
- certain pharmaceutical
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 abstract 1
- 229950001617 omecamtiv mecarbil Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan ciertas formulaciones farmacéuticas de omecamtiv mecarbil y métodos para su preparación y uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785763P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095542A1 true AR095542A1 (es) | 2015-10-21 |
Family
ID=50549466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101155A AR095542A1 (es) | 2013-03-14 | 2014-03-14 | Compuestos heterocíclicos y sus usos |
Country Status (41)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2970123T3 (pl) | 2013-03-14 | 2020-03-31 | Amgen Inc. | Sól omekamtywu mekarbilu i sposób otrzymywania soli |
TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
WO2019006235A1 (en) * | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
HUE052049T2 (hu) * | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
AU2019321573A1 (en) | 2018-08-17 | 2021-03-04 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
US20220185791A1 (en) * | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
SG11202109891WA (en) * | 2019-03-12 | 2021-10-28 | Amgen Inc | Polymorphs and cocrystals of a cardiac troponin activator |
US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2021070123A1 (en) * | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
BR112022015457A2 (pt) * | 2020-02-10 | 2022-10-04 | Amgen Inc | Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido |
EP4243825A1 (en) | 2020-11-12 | 2023-09-20 | Amgen Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
BR112023018095A2 (pt) | 2021-03-10 | 2023-12-12 | Amgen Inc | Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo |
WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788775B1 (fr) * | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
US20020015731A1 (en) | 1999-12-23 | 2002-02-07 | Appel Leah E. | Hydrogel-Driven Drug Dosage Form |
GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
EP1438043A2 (en) | 2001-10-17 | 2004-07-21 | Aventis Pharma Deutschland GmbH | Method of reducing type 2 diabetes in high risk patients |
US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
WO2007054975A1 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
PE20100742A1 (es) | 2005-11-15 | 2010-11-25 | Glaxo Group Ltd | Nuevos procedimientos y formulaciones |
TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7639112B2 (en) | 2007-04-25 | 2009-12-29 | Sony Corporation | Fuse device with integrated switch |
US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
JP5591245B2 (ja) | 2008-10-03 | 2014-09-17 | ペリコー セラピューティクス, インコーポレイテッド | 急性心不全の治療のための方法および組成物 |
US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
ES2733340T3 (es) * | 2013-03-14 | 2019-11-28 | Amgen Inc | Compuestos heterocíclicos y sus usos |
PL2970123T3 (pl) * | 2013-03-14 | 2020-03-31 | Amgen Inc. | Sól omekamtywu mekarbilu i sposób otrzymywania soli |
WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
WO2019006235A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
AU2019321573A1 (en) | 2018-08-17 | 2021-03-04 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
US20220042055A1 (en) | 2018-12-18 | 2022-02-10 | Amgen Inc. | Method of reducing aromatic nitro compounds |
WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
WO2021070123A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
WO2021136477A1 (zh) | 2020-01-03 | 2021-07-08 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
BR112022015457A2 (pt) | 2020-02-10 | 2022-10-04 | Amgen Inc | Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido |
EP4243825A1 (en) | 2020-11-12 | 2023-09-20 | Amgen Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
BR112023018095A2 (pt) | 2021-03-10 | 2023-12-12 | Amgen Inc | Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo |
-
2014
- 2014-03-14 PL PL14720369T patent/PL2970123T3/pl unknown
- 2014-03-14 MA MA44637A patent/MA44637B1/fr unknown
- 2014-03-14 MX MX2015012414A patent/MX363347B/es unknown
- 2014-03-14 HU HUE14719472A patent/HUE052355T2/hu unknown
- 2014-03-14 WO PCT/US2014/027146 patent/WO2014152270A1/en active Application Filing
- 2014-03-14 NZ NZ711225A patent/NZ711225A/en unknown
- 2014-03-14 SG SG11201507258PA patent/SG11201507258PA/en unknown
- 2014-03-14 CN CN201480014897.1A patent/CN105120844A/zh active Pending
- 2014-03-14 RS RS20191313A patent/RS59536B1/sr unknown
- 2014-03-14 CA CA2902436A patent/CA2902436A1/en active Pending
- 2014-03-14 SG SG10201706656RA patent/SG10201706656RA/en unknown
- 2014-03-14 RU RU2015143643A patent/RU2663663C2/ru active
- 2014-03-14 BR BR112015022857-7A patent/BR112015022857B1/pt active IP Right Grant
- 2014-03-14 EA EA201591728A patent/EA031185B1/ru unknown
- 2014-03-14 SI SI201431724T patent/SI2968173T1/sl unknown
- 2014-03-14 MA MA38399A patent/MA38399B2/fr unknown
- 2014-03-14 PT PT147203699T patent/PT2970123T/pt unknown
- 2014-03-14 TW TW103109296A patent/TWI667026B/zh active
- 2014-03-14 US US14/210,713 patent/US9951015B2/en active Active
- 2014-03-14 ME MEP-2019-283A patent/ME03566B/me unknown
- 2014-03-14 CN CN201810812212.8A patent/CN108785265A/zh active Pending
- 2014-03-14 ES ES14720369T patent/ES2750676T3/es active Active
- 2014-03-14 AU AU2014239995A patent/AU2014239995B2/en active Active
- 2014-03-14 KR KR1020227007907A patent/KR102474467B1/ko active IP Right Grant
- 2014-03-14 EP EP14719472.4A patent/EP2968173B1/en active Active
- 2014-03-14 CN CN201480018405.6A patent/CN105209437B/zh active Active
- 2014-03-14 AP AP2015008789A patent/AP2015008789A0/xx unknown
- 2014-03-14 LT LT14720369T patent/LT2970123T/lt unknown
- 2014-03-14 JP JP2016502348A patent/JP6783138B2/ja active Active
- 2014-03-14 PT PT147194724T patent/PT2968173T/pt unknown
- 2014-03-14 PE PE2015002000A patent/PE20151786A1/es unknown
- 2014-03-14 EP EP14720369.9A patent/EP2970123B1/en active Active
- 2014-03-14 JP JP2016502336A patent/JP6498658B2/ja active Active
- 2014-03-14 ES ES14719472T patent/ES2837038T3/es active Active
- 2014-03-14 SI SI201431358T patent/SI2970123T1/sl unknown
- 2014-03-14 BR BR112015023417-8A patent/BR112015023417B1/pt active IP Right Grant
- 2014-03-14 KR KR1020157025283A patent/KR102374159B1/ko active IP Right Grant
- 2014-03-14 MY MYPI2015002299A patent/MY186048A/en unknown
- 2014-03-14 HU HUE14720369A patent/HUE046285T2/hu unknown
- 2014-03-14 EP EP20201011.2A patent/EP3821882A1/en active Pending
- 2014-03-14 UY UY0001035449A patent/UY35449A/es active IP Right Grant
- 2014-03-14 CA CA3147180A patent/CA3147180C/en active Active
- 2014-03-14 UA UAA201509685A patent/UA117011C2/uk unknown
- 2014-03-14 WO PCT/US2014/027104 patent/WO2014152236A1/en active Application Filing
- 2014-03-14 LT LTEP14719472.4T patent/LT2968173T/lt unknown
- 2014-03-14 DK DK14720369.9T patent/DK2970123T3/da active
- 2014-03-14 RS RS20201513A patent/RS61215B1/sr unknown
- 2014-03-14 CA CA2902646A patent/CA2902646C/en active Active
- 2014-03-14 AU AU2014240049A patent/AU2014240049C1/en active Active
- 2014-03-14 US US14/773,436 patent/US9988354B2/en active Active
- 2014-03-14 PL PL14719472T patent/PL2968173T3/pl unknown
- 2014-03-14 AR ARP140101155A patent/AR095542A1/es not_active Application Discontinuation
- 2014-03-14 MX MX2015012429A patent/MX2015012429A/es unknown
- 2014-03-14 DK DK14719472.4T patent/DK2968173T3/da active
- 2014-03-16 JO JOP/2014/0114A patent/JOP20140114B1/ar active
-
2015
- 2015-08-24 IL IL240788A patent/IL240788B/en active IP Right Grant
- 2015-08-31 TN TN2015000380A patent/TN2015000380A1/en unknown
- 2015-09-03 IL IL24108915A patent/IL241089B/en active IP Right Grant
- 2015-09-08 PH PH12015501998A patent/PH12015501998B1/en unknown
- 2015-09-11 MX MX2021001231A patent/MX2021001231A/es unknown
- 2015-09-14 CL CL2015002708A patent/CL2015002708A1/es unknown
- 2015-09-14 SA SA515361088A patent/SA515361088B1/ar unknown
- 2015-10-13 CR CR20150549A patent/CR20150549A/es unknown
-
2016
- 2016-06-02 HK HK16106250.4A patent/HK1218080A1/zh unknown
- 2016-06-07 HK HK16106547.7A patent/HK1218544A1/zh unknown
- 2016-06-07 HK HK16106548.6A patent/HK1218512A1/zh unknown
- 2016-06-30 HK HK16107606.3A patent/HK1219484A1/zh unknown
-
2018
- 2018-03-20 US US15/926,411 patent/US10421726B2/en active Active
- 2018-04-26 US US15/963,529 patent/US20180312469A1/en not_active Abandoned
- 2018-11-15 JP JP2018214801A patent/JP6689942B2/ja active Active
-
2019
- 2019-01-24 PH PH12019500176A patent/PH12019500176A1/en unknown
- 2019-09-23 US US16/579,360 patent/US11384053B2/en active Active
- 2019-09-24 HR HRP20191728 patent/HRP20191728T1/hr unknown
- 2019-10-15 CY CY20191101080T patent/CY1122695T1/el unknown
- 2019-11-14 US US16/684,216 patent/US20200079736A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069487A patent/JP6966590B2/ja active Active
- 2020-07-02 US US16/920,144 patent/US11472773B2/en active Active
- 2020-07-02 US US16/920,155 patent/US20200331859A1/en not_active Abandoned
- 2020-12-08 HR HRP20201967TT patent/HRP20201967T1/hr unknown
- 2020-12-15 CY CY20201101184T patent/CY1123633T1/el unknown
-
2021
- 2021-09-24 US US17/448,833 patent/US11958809B2/en active Active
- 2021-10-21 JP JP2021172324A patent/JP7174132B2/ja active Active
-
2022
- 2022-06-08 US US17/806,033 patent/US11884630B2/en active Active
- 2022-09-08 US US17/930,695 patent/US20230044617A1/en active Pending
-
2023
- 2023-11-27 US US18/520,156 patent/US20240101517A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150549A (es) | Compuestos heterocíclicos y sus usos | |
ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
CR20140460A (es) | Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona | |
CL2016000981A1 (es) | Formulaciones de estrigolactona y sus usos | |
CO2017004714A2 (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
NI201300080A (es) | Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos | |
UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
NI201600015A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
UY34603A (es) | Anticuerpos anti-asic-1 y usos de los mismos | |
ES2970186T3 (es) | Formulaciones farmacéuticas y métodos de uso de las mismas | |
CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
UY35876A (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
CL2014003423A1 (es) | Formulaciones antibióticas inyectables y sus métodos de uso. | |
UY37009A (es) | Formulaciones granuladas de giberelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |